Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Kintara Therapeutics, Inc. (KTRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.70-1.16 (-13.09%)
At close: 04:00PM EST
7.92 +0.22 (+2.86%)
After hours: 07:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close8.86
Open9.20
Bid7.77 x 1200
Ask7.92 x 800
Day's Range7.37 - 9.53
52 Week Range3.50 - 42.00
Volume716,136
Avg. Volume349,064
Market Cap12.444M
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KTRA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kintara Therapeutics, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Insider Monkey

    10 Pump and Dump Stocks Hedge Funds Like

    In this article, we discuss the 10 pump and dump stocks hedge funds like. If you want to read about some more pump and dump stocks, go directly to 5 Pump and Dump Stocks Hedge Funds Like. The influx of retail investors on the stock market in recent months and the rise of social media […]

  • InvestorPlace

    7 Penny Stocks With 10x Potential This Year

    Penny stocks can multiply in value quickly, these picks have 10x potential this year. Regulus Therapeutics (RGLS): Represents traditional pharma potential and proven returns for traders. Imperial Petroleum (IMPP): Traders have shown their appreciation for Imperial Petroleum which has already gone 10X this year. Kintara Therapeutics (KTRA): A pharma firm that’s on the edge but analysts believe it has 20X potential built in. ObsEva (OBSV): Female reproductive health biotech with a significant cata

  • Simply Wall St.

    Here's Why Kintara Therapeutics (NASDAQ:KTRA) Must Use Its Cash Wisely

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Advertisement
Advertisement